You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

Disappointing drug results sink ArQule

Woburn-based ArQule Inc. develops cancer therapies.

Joanne Rathe/Globe Staff/File

Woburn-based ArQule Inc. develops cancer therapies.

An experimental colorectal cancer drug being developed by Woburn’s ArQule Inc. and Japan’s Daiichi Sankyo Co. Ltd. failed to improve patient survival without the cancer worsening. The midstage trial, which enrolled 122 patients, also failed to meet the secondary goal of showing improved response to the drug tivantinib. Friday’s failure is the latest in a series of bad drug-related news. It ended a lung cancer trial in October and an Asian partner halted another trial in August.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of